Dimitris Boufidis

Dimitris Boufidis

Auto-generated profile, based on publicly available information

Dimitris Boufidis

Center of Neuroengineering and Therapeutics University of Pennsylvania Philadelphia Pennsylvania USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DBDimitris Boufidis
Dimitris Boufidis
RGRaghav Garg
Raghav Garg
EAEugenia Angelopoulos
Eugenia Angelopoulos
DCD. Kacy Cullen
D. Kacy Cullen
FVFlavia Vitale
Flavia Vitale
Neural interface technologies are increasingly evolving towards bio-inspired approaches to enhance integration and long-term functionality. Recent strategies merge soft materials with tissue engineering to realize biologically-active and/or cell-containing living layers at the tissue-device interface that enable seamless biointegration and novel cell-mediated therapeutic opportunities. This review maps the field of bio-inspired electronics and discusses key recent developments in tissue-like and regenerative bioelectronics, from soft biomaterials and surface-functionalized bioactive coatings to cell-containing ‘biohybrid’ and ‘all-living’ interfaces. We define and contextualize key terminology in this emerging field and highlight how biological and living components can bridge the gap to clinical translation.

18 August 2025 in Advanced Materials Interfaces
Verified
Journal Article
Open access
DBDimitris Boufidis
Dimitris Boufidis
EKElizabeth N. Krizman
Elizabeth N. Krizman
CSCybelle M. Smith
Cybelle M. Smith
YXYihan Xie
Yihan Xie
RGRaghav Garg
Raghav Garg
DCD. Kacy Cullen
D. Kacy Cullen
Astrocytes, the most abundant cell type in the brain, are increasingly recognized as active regulators of neuronal function and potential therapeutic targets. Two‐dimensional MXenes, such as titanium carbide (Ti 3 C 2 T x ), hold promise for neural interfaces and bioelectronic applications owing to their favorable electrochemical properties, but their compatibility with glial cells has yet to be investigated. Here, the first systematic evaluation of astrocyte–MXene interactions is reported by exposing cortical rat astrocytes to varying concentrations of Ti 3 C 2 T x in aqueous dispersions. Phase contrast and scanning electron microscopy showed individual flakes and larger aggregates on astrocyte membranes with no detectable damage. Cytotoxicity assays demonstrated robust astrocyte viability, morphological analysis indicated no significant changes in cell structure, and calcium imaging revealed no changes in spontaneous Ca 2 ⁺ activity between control and Ti 3 C 2 T x ‐treated cultures. These findings establish a foundation for the integration of Ti 3 C 2 T x into next‐generation neural interfaces while underscoring the need for further exploration of MXene‐based tools for astrocyte‐targeted neuromodulation.

25 September 2026 in Advanced Materials
Verified
Journal Article
Open access
PDF file
RGRaghav Garg
Raghav Garg
FLFranco A. Laimo
Franco A. Laimo
SIStefano Ippolito
Stefano Ippolito
PUPrastuti Upadhyay
Prastuti Upadhyay
SASpencer R. Averbeck
Spencer R. Averbeck
FVFlavia Vitale
Flavia Vitale
Implantable bioelectronics for acute neural applications must combine tissue‐like mechanics with high electrochemical performance while enabling safe biodegradation to avoid risks associated with explant surgeries. Here, we present MXgel bioelectronics, a soft and fully transient hydrogel platform that enables high‐fidelity electrophysiological recordings and effective stimulation with programmable degradation under physiological conditions. The platform employs polymer‐free Ti 3 C 2 T x MXene hydrogels (MXgel) that achieve exceptional electrical conductivities (hydrated: 790 ± 150 S m −1 , freeze‐dried: 4420 ± 576 S m −1 ). Integrated on biodegradable gelatin‐based substrates, MXgel bioelectronics exhibit low electrochemical impedance (1.06 ± 0.37 kΩ at 1 kHz), 25‐fold higher cathodic charge storage (207.1 ± 48.8 mC cm −2 ), and 10‐fold greater charge injection capacity (0.24 ± 0.08 mC cm −2 ) than conventional clinical electrodes. We demonstrate that these properties enable cortical and peripheral neural recordings with ∼60 dB signal‐to‐noise ratio and effective neuromodulation. Moreover, MXgel bioelectronics undergo safe degradation under physiological conditions with predictable and tunable kinetics. Importantly, MXgel bioelectronics do not trigger severe foreign body reaction, and their degradation byproducts do not accumulate in the body, confirming safe systemic clearance. Together, these results establish MXgel bioelectronics as a clinically relevant platform for soft, high‐performance, and transient neural interfaces.